Bitamin K2 (MK‑7) da Ya Rage Taruwar Calcium a Jijiyoyin Zuciya Bayan Shekaru 2
Wani ƙananan magani da ake sayarwa a kasuwa ya yi wani abu a wani gwajin ƙwafi‑ƙwafi da mafi yawan ƙwayoyin gina jiki ba su iya cimmawa: ya rage auna ƙaruwa da calcium a jijiyoyin zuciya na mutanen da ke da cutar zuciya tun da da. Abu ɗaya da ke da ƙalubale, kuma akwai, shi ne babu wanda ya tabbatar har yanzu ko wannan yana hana faɗuwar zuciya ɗaya.
Maganin bitamin K2 a matsayin menaquinone‑7 (MK‑7) ne. Gwajin ya kasance VitaK‑CAC, wanda aka buga a JAMA Cardiology a shekarar 2026.
Lambar Muƙamuɗi
Masu shiga gwajin suna da cutar jijiyoyin zuciya mai alamun ciwo (CAD) tare da ƙimar calcium a jijiyoyin zuciya (CAC) tsakanin 50 zuwa 400 Agatston units (AU). Sun sha 360 µg na MK‑7 a kowace rana ko placebo daidai da gwargwado tsawon shekaru biyu. Matsakaicin ƙimar CAC a kowanne rukuni ya canza kamar haka:
| Rukuni | Farko | Shekara 1 | Shekara 2 |
|---|---|---|---|
| Placebo | 145 AU | 173 AU | 214 AU |
| MK‑7 (360 µg/ran) | 135 AU | 150 AU | 184 AU |
Wannan na nufin haɓakar da ta kai kimanin 49 AU a rukuni na MK‑7, yayin da a rukuni placebo ta kai 69 AU. Bambanci tsakanin rukuni‑rukuni ya kasance na ƙididdiga (P = .02), har ma bayan da aka daidaita da sauran ƙimomi. Maƙasudin calcium da aka auna ta hanyar CT ya nuna irin wannan sakamako.
Calcification ya ci gaba da faruwa a rukuni na MK‑7, amma a hankali.
Waɗanda Aka Bincika
Masana sun ba da ƙwayoyin 180 ga mutane, 90 a kowanne rukuni, a asibitin jami’a guda ɗaya da asibitin ƙauye a ƙasar Netherlands. An tantance bayanai daga marasa lafiya 85 a rukuni na MK‑7 da 82 a rukuni na placebo.
- Shekaru: matsakaicin shekara 59 (MK‑7) da 61 (placebo)
- Jinsi: kashi 42% mata a dukkan rukuni
- Yanayi: CAD mai alamun ciwo tare da calcium matsakaici (CAC 50‑400 AU)
- Daidaiton asali: rukuni biyu suna kusan daidai
Wannan rukuni ne matasa‑tsakanin shekaru, tare da calcium da aka tabbatar amma ba mai tsanani ba. Sakamakon zai iya bambanta ga mutanen da ke da CAC mai tsanani, marasa alamar ciwo, ko masu fama da cutar ƙoda.
Ba Sai An Duba CAC Kaɗai Ba: Cikakken Bayani Akan Plaque
Abu mafi ban sha’awa a cikin takardar shine inda tasirin ya fito. Masu gwajin sun kuma yi CT angiography, wanda ke ba da damar ganin nau’in plaque. Haɓakar CAC ta yi daidai da yawan plaques marasa calcium da suka fara samun wani sashi na calcium a lokacin gwajin (R² = 0.17; P = .04).
Masu rubutun sun yi bayanin cewa MK‑7 na iya rage kalkulashan a plaques marasa calcium. Dangantakar R² = 0.17 ba ta da karfi sosai, don haka akwai sauran abubuwa da suka fi tasiri. Wannan na nuni da wata yiwuwar hanya, ba da tabbacin cikakken mechanisme ba.
Akwai kuma wani gwaji na ilimin halittu. Matakin MK‑7 a jini ya tashi daga matsakaicin 0.50 µg/L zuwa 6.56 µg/L a rukuni na magani (P < .001), wanda ke nuna cewa masu shiga gwajin sun sha maganin kuma jikin su ya shaƙa shi. Wannan yana da muhimmanci domin matsalar rashin ɗaukar magani na iya shafar sakamakon gwaje‑gwaje.
Tsaro
Masu binciken sun bayar da babu wata mummunar illa da ta tasiri. Don gwajin shekaru biyu na ƙwayar gina jiki, wannan alama ce mai gamsarwa, ko da yake gwajin ba zai iya gano matsaloli masu zamewa ba.
Abubuwan Da Ba Mu Sani Ba
Wannan shi ne inda ake buƙatar iyakancewa a kan labarin.
- Mahimmancin likita ba a tabbatar ba. Masu rubutun sun ce “mahimmancin wannan sakamako a bangaren ƙarfafa plaque har yanzu ba a tantance ba.” Rage kalkulashan alama ce ta hoton hoto, ba rage bugun zuciya, bugun jini, ko mutuwa ba. Calcium ma alama ce mai rikitarwa – wasu plaques masu calcium na iya zama ƙarfi fiye da waɗanda ba su da calcium, don haka rage kalkulashan ba yana nufin alheri ba.
- Bambancin da aka samu ƙanana ne. Kimanin 20 AU kawai ne ya raba ƙaruwa a rukuni biyu a tsawon shekaru biyu.
- Gwajin ba shi da girma sosai. Mutane 167 da aka tantance ya isa don gano bambancin CAC, amma ba zai iya gano bambancin abubuwan kiwon lafiya ba.
- Lokacin gwajin ya yi tsawo da ɗan tsangwama. An tattara bayanai daga 2012 zuwa 2022 “tare da wasu ɗan tsangwama.”
- Akwai alaƙa da masana’anta. Prof. Leon Schurgers ya bayyana cewa ya karɓi tallafi daga Gnosis by Lesaffre (masana'antar MK‑7) da kuma hannun jari a Coagulation Profile, duk da cewa ba su shiga cikin aikin da aka gabatar ba. Wannan ba ya kawar da sakamakon, amma yana da mahimmanci a sani. Wani sharhi a cikin bugun mujallar ya ƙara yin nazari kan wannan sakamako.
Abubuwan Da Za A Iya Yi Da Su
Kima: Gwajin ya yi amfani da 360 µg na MK‑7 a kowace rana. Wannan shine kawai ƙimar da ke da hujja daga wannan bincike, kuma ya fi yawa fiye da yadda ake samu a yawancin multivitamins.
Nau’in: MK‑7, ba MK‑4. An gwada menaquinone‑7 kawai. Ba a gwada MK‑4 ko bitamin K1 ba, don haka ba za a iya ɗauka cewa waɗannan suna da irin tasirin ba. Hakanan an gwada MK‑7 da placebo kadai, ba a haɗe shi da wasu ƙwayoyi ba.
Lokaci: Babu cikakken bayani a takardar kan lokacin da aka ɗauki maganin. Bitamin K ya fi narkewa a abinci mai ɗan mai, don haka a ci da abinci da ke ɗauke da mai zai fi dacewa. Wannan ba gwajin da aka yi ba ne, amma shawara ce mai ma’ana.
Waɗanda zai iya amfana: Sakamakon ya shafi mutane kamar waɗanda aka zaɓa – manya‑tsakiyar shekaru da ke da CAD mai alamun ciwo da calcium matsakaici. Idan kai ko wani da ka sani yana cikin wannan yanayin, yana da kyau a tattauna da likitan zuciya. Ba zai maye gurbin statins, kulawar hawan jini, ko sauran magungunan da aka tabbatar ba.
Waɗanda ya kamata su guje shi ko su tambaya da farko:
- Kowa da ke shan warfarin ko wani maganin hana coagulation da ke kan vitamin K. Bitamin K na iya shafar yadda waɗannan magunguna ke aiki, kuma zai iya canza INR. Kada ka fara amfani da MK‑7 ba tare da izinin likita ba.
- Masu shan wasu anticoagulants ko masu tarihin clotting, su tuntuɓi likita kafin su sha.
- Wanda ke tunanin zai “mayar da” calcium. Gwajin ya nuna rage ƙaruwa, ba maimaita ba.
- Waɗanda ba su da cutar zuciya. Wannan gwaji ba ya ba da shaidar amfanin MK‑7 ga mutanen da ba su da CAD.
Ƙarshe
VitaK‑CAC gwaji ne da aka tsara da kyau, tare da placebo, kuma ya nuna rashin ƙaruwa a kalkulashan jijiyoyin zuciya da ke da sahihanci a ƙididdiga da kuma daɗin lafiya mai kyau. Wannan yana da ƙarfafa guiwa ga masu bincike, musamman da alamar da aka samu a plaques marasa calcium. Amma sakamakon yana daga alamar auna hoton ne, daga gwaji ƙanana, tare da wani bayani na rikicin sha’awa da ya kamata a lura da shi. Sai gwaje‑gwaje mafi girma su nuna rage yawan abubuwan da suka faru a zuciya, kafin a ɗauke MK‑7 a matsayin magani mai ƙarfi; a halin yanzu, yana iya zama ƙari mai amfani da za a tattauna da likitan ka.
Manazo: Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two Years of Menaquinone‑7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiology. 2026;11(8):719‑726. doi:10.1001/jamacardio.2026.1279. ClinicalTrials.gov: NCT01002157. PubMed.